Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Ocugen Earnings Call: Key Takeaways

Ocugen is transitioning to a late-stage clinical company with three Phase 3 programs, targeting BLA filings by 2028 and leveraging international licensing for non-dilutive capital.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceHigh confidence in OCU400 power analysis showing 93.2% power at 20% response.
Margin TrendsR&D expenses rose to $12.5M from $11.1M year-over-year.
Pricing PowerBahamas EAP pricing expected to match US commercial pricing levels.
Segment GrowthOCU410 for GA identified as the largest commercial opportunity.
New ClientsExclusive OCU400 license for MENA with Roots Pharma; $4M upfront/milestones.
Capex & DebtCash balance of $84.6M expected to support runway into 2028.
RegulatoryOCU400 received provisional approval in Bahamas under LARDA; full approval expected year-end.
CommentaryModifier gene therapy platform is gene-agnostic, addressing underlying biology across multiple networks.
New LaunchesEstablished European presence to support pre-commercial activities and clinical development.

Growth

Q3 2026 operating expenses were $19.7M; net loss per share improved to $0.01.

Outlook

Targeting three BLA filings by 2028; OCU400 Phase 3 top-line data expected Q1 2027.

Risks

Management pivoted on Stargardt interim efficacy, citing small sample size and baseline heterogeneity for lack of modification.

Source

The company's earnings call, NASDAQ: OCGN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Ocugen, Inc.: key numbers

Share price
$0.7730Close, Nov 16
Market cap
$262M
Shares outstanding
339.31MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ocugen, Inc.

All →
8:31 AM ET 8-K
Licensing Deal

Ocugen Licensing Deal with Celairis Therapeutics Holdings Pty Ltd Worth $7.1M

Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.

Value
$7.1M
Counterparty
Celairis Therapeutics Holdings Pty Ltd
Term
20 years
9:44 AM ET 10-Q
Financial Results ▶ Call

Ocugen Q3 2026 Results: Net Loss of $3.6M, Loss Narrows

Ocugen, Inc. reported total assets of $108.1 million as of September 30, 2026, a significant increase from $43.5 million at the end of 2025, primarily driven by $59.6 million in new short-term investments. The company is currently advancing its Phase 3 trial for OCU400 and Phase 2/3 trial for OCU410ST while maintaining its status as a non-accelerated filer and smaller reporting company.

Key figure
Net loss $3.6M
8:29 AM ET 8-K
Financial Results

Ocugen Financial Results

Ocugen reported Q3 2026 financial results, highlighting a cash position of $84.6 million with an expected runway into 2028. The company advanced its gene therapy pipeline, including the initiation of the Phase 3 ArMaDa3 trial for OCU410 and receiving provisional approval for OCU400 in The Bahamas.

Term
Q3 2026

“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide.”

Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen

“As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”

Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen
8:01 AM ET 8-K
Investor Presentation

Ocugen Investor Presentation

Ocugen, Inc. filed a formal investor presentation deck for October 2026 detailing its strategic pipeline and clinical milestones. The company is targeting three Biologics License Applications (BLAs) by 2028 for its gene therapy candidates OCU400, OCU410, and OCU410ST, which address major blindness diseases.

6:07 AM ET 8-K
Licensing Deal

Ocugen Licensing Deal with Roots Pharmaceutical Company WLL Worth $259M

Ocugen granted Roots Pharmaceutical an exclusive license to commercialize OCU400, a modifier gene therapy for retinitis pigmentosa, in the Middle East and North Africa. Ocugen will receive up to $4 million in upfront and development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen also entered into a commercial supply agreement to manufacture the product for Roots.

Value
$259M
Counterparty
Roots Pharmaceutical Company WLL
Term
20 years from first commercial sale
9:07 PM ET Form 4
Insider Selling

Ocugen CEO Shankar Musunuri Sells $500K of Stock

Shankar Musunuri, CEO, sold 525,991 shares of Ocugen, Inc. at $0.95 a share, worth $500K in total on Oct 9, 2026. Shares held after the trade: 1,030,771 (-5.3%).

Value
$500K
Shares
525,991
Average price
$0.9500
Role
CEO
Holding change
-5.3%
Trade date
Oct 9, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.